Janus Henderson Group PLC Purchases Shares of 2,271,832 Protara Therapeutics, Inc. (NASDAQ:TARA)

Janus Henderson Group PLC acquired a new stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,271,832 shares of the company's stock, valued at approximately $11,938,000. Janus Henderson Group PLC owned approximately 11.01% of Protara Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the company. RA Capital Management L.P. increased its position in shares of Protara Therapeutics by 78.9% during the fourth quarter. RA Capital Management L.P. now owns 3,400,000 shares of the company's stock valued at $17,952,000 after acquiring an additional 1,500,000 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in Protara Therapeutics during the 4th quarter valued at $11,880,000. Blackstone Inc. bought a new stake in shares of Protara Therapeutics in the 4th quarter worth $8,870,000. Acorn Capital Advisors LLC purchased a new position in shares of Protara Therapeutics in the fourth quarter worth $6,757,000. Finally, 5AM Venture Management LLC bought a new position in shares of Protara Therapeutics during the fourth quarter valued at $4,224,000. 38.13% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Protara Therapeutics

In other Protara Therapeutics news, insider Jacqueline Zummo sold 21,224 shares of the company's stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total value of $96,144.72. Following the completion of the sale, the insider now owns 98,861 shares in the company, valued at $447,840.33. This represents a 17.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 8.40% of the stock is owned by company insiders.

Protara Therapeutics Trading Up 0.3%

NASDAQ TARA traded up $0.01 during trading hours on Thursday, hitting $3.26. 130,403 shares of the company's stock traded hands, compared to its average volume of 767,601. Protara Therapeutics, Inc. has a 52 week low of $1.60 and a 52 week high of $10.48. The firm has a market capitalization of $125.78 million, a P/E ratio of -1.16 and a beta of 1.73. The business's fifty day moving average price is $3.88 and its two-hundred day moving average price is $4.14.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.18. On average, sell-side analysts expect that Protara Therapeutics, Inc. will post -3.32 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on TARA shares. Scotiabank started coverage on Protara Therapeutics in a report on Wednesday, April 16th. They issued a "sector outperform" rating and a $12.00 price objective for the company. Jones Trading began coverage on shares of Protara Therapeutics in a research note on Thursday. They issued a "buy" rating and a $21.00 price target for the company. Lifesci Capital assumed coverage on shares of Protara Therapeutics in a research report on Tuesday, March 11th. They set an "outperform" rating and a $22.00 price objective on the stock. Cantor Fitzgerald initiated coverage on shares of Protara Therapeutics in a research report on Friday, March 14th. They issued an "overweight" rating for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $23.00 target price on shares of Protara Therapeutics in a research note on Monday, April 28th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Protara Therapeutics presently has an average rating of "Buy" and a consensus target price of $20.50.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.